Skip to main content

Table 2 Adverse events observed in untreated and drug-treated patients with borderline or less severe PH

From: Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis—an interim analysis of results from a prospective, single-center, randomized, parallel-group study

 

Untreated borderline or less severe PH

Drug-treated borderline or less severe PH

Exacerbation of dyspnea

7

3

Time to exacerbation of dyspnea (mean ± SD) (days)

152.00 ± 89.94

259.00 ± 49.37

Increase of the O2 dose

5

2

Time to O2 dose increase (mean ± SE) (days)

199.00 ± 132.90,

335.00 ± 182.43

Decrease of the O2 dose

0

1

Hospitalization (hospital-free survival)

8 (241.50 ± 192.24)

2 (239.002 ± 169.00)

Death (survival)

7 (309.29 ± 195.13)

1 (671)

Other adverse events

3a

6b

  1. a Gastrointestinal hemorrhage (n = 1), pneumonia (n = 1), and ileus (n = 1)
  2. b Pneumothorax (n = 3), CHF (n = 2), and liver dysfunction (n = 1)
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us